title: Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
abstract: The single i.v. dose kinetics of a fixed combination of imipenem/cilastatin were investigated in ten critically ill patients treated by continuous arteriovenous haemofiltration (CAVH). Eight patients suffered from acute renal failure and two had normal renal function. Both drugs were measured in plasma and ultrafiltrate by high-performance liquid chromatography. While the pharmacokinetics of both drugs are almost identical in patients with normal renal function, we found the following dissociation of pharmacokinetic parameters in our patients with renal failure: for imipenem the total clearance and elimination half-life was 104 +/- 12 ml/min and 2.2 +/- 0.1 h, respectively, and for cilastatin 29 +/- 10 ml/min and 13.8 +/- 4.5 h. The pharmacokinetics of imipenem and cilastatin differ from each other in renal failure because imipenem, unlike cilastatin, undergoes marked elimination by non-renal pathways. Our results did not differ from previously reported data in healthy volunteers and patients with impaired renal function. Elimination of imipenem by CAVH was low (7% of the dose). As a consequence of the unsatisfactory non-renal clearance of cilastatin, however, the fraction of the dose removed by CAVH was significantly greater (approximately 30%) than that of imipenem. This did not, however, correct the dissociation of the pharmacokinetic profiles of the two drugs. In conclusion, the dose of imipenem/cilastatin in critically ill patients with renal failure treated by CAVH should be modified according to renal function but elimination by CAVH does not need to be considered.
authors.affiliation: Department of Nephrology, University of Freiburg, FRG.
authors.forename: E
authors.initials: E
authors.lastname: Keller
authors.forename: H
authors.initials: H
authors.lastname: Fecht
authors.forename: J
authors.initials: J
authors.lastname: Böhler
authors.forename: P
authors.initials: P
authors.lastname: Schollmeyer
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications / Q000378:metabolism / Q000628:therapy; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D015377:Cilastatin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D003422:Critical Care; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D006440:Hemofiltration; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged
chemical_list: D015377:Cilastatin; D015378:Imipenem